Case Studies
![](https://boydconsultants.com/wp-content/uploads/2023/10/Website-news-cover-image-size-57-300x225.png)
Regulatory support for the development of a stem cell therapy and device for the treatment of Parkinson’s Disease
Boyds provided regulatory support to an academic institution client with an exciting proposal for a first-in-human stem cell therapy trial involving a medical device for the treatment of Parkinson’s Disease.
![](https://boydconsultants.com/wp-content/uploads/2023/08/Website-news-cover-image-size-45-300x225.png)
Providing support for a phase 2 study in patients with metastatic breast cancer in the UK and EU
Boyds provided services to assist an EU Sponsor with the set up and ongoing site management of a study in patients with advanced metastatic breast cancer in the UK and Spain.
![study start-up support](https://boydconsultants.com/wp-content/uploads/2023/07/Website-news-cover-image-size-35-300x225.png)
Strategic study start-up support in the UK and Europe
Boyds was engaged to support a client in the US with study start-up services in the UK and France for a gene therapy study in patients with an ocular condition.
![Gene therapy expertise](https://boydconsultants.com/wp-content/uploads/2023/05/Website-news-cover-image-size-25-300x225.png)
Combined gene therapy expertise supports US biotech
The client was an early-stage start-up in the pre-clinical stage of developing a suite of gene therapy products for a cardiovascular indication.
![](https://boydconsultants.com/wp-content/uploads/2023/04/Website-news-cover-image-size-17-300x225.png)
Expansion of oncology clinical programme into other indications
The client came to Boyds with an exciting cell therapy programme that released its active molecule selectively in solid tumour cells.
![](https://boydconsultants.com/wp-content/uploads/2023/04/Website-news-cover-image-size-16-300x225.png)
Supporting new biotech companies spinning out of academia
Boyds played an important role in the formation of academia spin-out, Axovia, by providing technical and strategic support, alongside product development plans for the company’s drug programmes.